Deals in Depth: December 2008
December 2008 dealmaking highlights: after losing GSK as a partner for XL184 and XL281, Exelixis ended up licensing the oncology compounds to BMS in the biggest alliance of December at a pre-commercial value of $850 million. J&J again topped the M&A list with its takeover of aesthetic devices company Mentor for $1.1 billion, but St. Jude Medical should get honorary mentioning as it made two big acquisitions--Radi and MediGuide--to add to its cardiovascular products. Financing in biopharma and device firms ended 2008 on a weak note, low in terms of both volume of deals and dollars raised. All December deals were private placements, with those done by public Rx companies slightly edging out the VC financing with 41% of the total. Device fund-raising, slightly up from last month to $113 million, saw the bulk of the money in early venture rounds.
You may also be interested in...
Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.